ALVR INVESTORS: Lead Plaintiff Deadline is Approaching; Contact Robbins LLP for Information About Your Rights
March 06, 2024 18:17 ET
|
Robbins LLP
AlloVir, Inc. (ALVR) Allegedly Misled Investors Regarding Efficacy of its posoleucel Phase 3 Studies
ALVR Shareholders Who Lost Money Should Contact Robbins LLP for Information About the AlloVir, Inc. Class Action
February 10, 2024 00:49 ET
|
Robbins LLP
AlloVir, Inc. (ALVR) Allegedly Misled Investors Regarding Efficacy of its posoleucel Phase 3 Studies
AlloVir, Inc. (ALVR) Stockholder News: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in AlloVir, Inc. Class Action
January 29, 2024 19:45 ET
|
Robbins LLP
AlloVir, Inc. (ALVR) Allegedly Misled Investors Regarding Efficacy of its posoleucel Phase 3 Studies
Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against AlloVir, Inc. (ALVR)
January 22, 2024 21:09 ET
|
Robbins LLP
AlloVir, Inc. (ALVR) Allegedly Misled Investors Regarding Efficacy of its posoleucel Phase 3 Studies